Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Eyepoint Pharmaceuticals Stock Up 0.9%

NASDAQ:EYPT opened at $15.07 on Tuesday. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $5.30 and a 52 week high of $19.11. The company has a market capitalization of $1.26 billion, a P/E ratio of -4.77 and a beta of 1.89. The stock’s fifty day moving average is $14.51 and its two-hundred day moving average is $14.57.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The business had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. Sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EYPT. HC Wainwright lifted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Citigroup raised their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Chardan Capital increased their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.20.

Institutional Trading of Eyepoint Pharmaceuticals

Large investors have recently modified their holdings of the stock. Cyndeo Wealth Partners LLC grew its position in shares of Eyepoint Pharmaceuticals by 3.4% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock worth $420,000 after buying an additional 760 shares in the last quarter. California State Teachers Retirement System grew its position in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares in the last quarter. RWC Asset Management LLP grew its position in shares of Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after buying an additional 1,040 shares in the last quarter. MCF Advisors LLC grew its position in shares of Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after buying an additional 1,149 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 11.0% during the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.